S&P 500 Healthcare stocks: today's ranking and data
The S&P 500 has 59 companies in Healthcare today. It accounts for 10.2% of the market value of the index companies. Its median P/E is 32.8, against 23.5 for the index as a whole.
What Healthcare is and what drives its earnings
What it includes. Drug makers and biotech, medical device and supply makers, health insurers and managed-care companies, drug distributors, hospitals and clinics, and diagnostics, lab and research-tools companies.
What drives its earnings. For drug makers, the patent cycle (when a drug's patent expires, generics arrive and its sales drop sharply), clinical trials and FDA approvals. Across the sector, drug pricing and what Medicare and Medicaid reimburse. For insurers, the gap between the premiums they collect and the medical costs they pay. And underneath it all, an aging population.
How it behaves. It is considered defensive because demand for health care depends little on the economic cycle, but it carries a risk of its own, regulatory and political: a change in drug pricing or public reimbursement hits many companies in the sector at once.
The classification is the one used by this site's data provider, similar to but not the same as GICS, S&P's standard: this sector roughly matches "Health Care". Counts may therefore differ from other sources.
All 59 stocks in the sector, by today's multi-factor rank
The rank is the order produced by a quantitative model on data as of Nov 13, 2026: the average of four factors (momentum, value, quality and growth) computed from public data, against the 463 index companies that score. It is a calculation, not a recommendation to buy or sell: it knows nothing about anyone's situation, horizon or risk, and the returns of portfolios built with it are simulated. How it is computed: see the methodology.
| In sector | Index rank | Company | P/E | Market cap |
|---|---|---|---|---|
| 1 | 17 of 463 | CVS CVS Health | 10.4 | $114.32B |
| 2 | 23 of 463 | CNC Centene | 24.4 | $35.28B |
| 3 | 24 of 463 | HUM Humana | 43.7 | $54.05B |
| 4 | 45 of 463 | ELV Elevance Health | 18.3 | $92.84B |
| 5 | 49 of 463 | LLY Eli Lilly | 46.9 | $1.29T |
| 6 | 64 of 463 | VTRS Viatris | — | $23.87B |
| 7 | 67 of 463 | ABBV AbbVie | 50.8 | $521.50B |
| 8 | 96 of 463 | DXCM DexCom | 32.8 | $31.08B |
| 9 | 120 of 463 | CI Cigna | 13.1 | $78.26B |
| 10 | 125 of 463 | RVTY Revvity | 68.6 | $17.24B |
| 11 | 135 of 463 | WST West Pharmaceutical Services | 46.7 | $29.01B |
| 12 | 140 of 463 | JNJ Johnson & Johnson | 43.4 | $687.89B |
| 13 | 144 of 463 | CAH Cardinal Health | 36.4 | $64.97B |
| 14 | 146 of 463 | HSIC Henry Schein | 23.6 | $9.53B |
| 15 | 153 of 463 | UNH UnitedHealth | 23.3 | $365.09B |
| 16 | 157 of 463 | MCK McKesson | 28.4 | $127.33B |
| 17 | 159 of 463 | DGX Quest Diagnostics | 25.9 | $28.56B |
| 18 | 163 of 463 | BMY Bristol-Myers Squibb | 14.1 | $129.66B |
| 19 | 171 of 463 | REGN Regeneron Pharmaceuticals | 21.1 | $98.84B |
| 20 | 172 of 463 | MRK Merck | 150.8 | $364.26B |
| 21 | 175 of 463 | UHS Universal Health Services | 8.1 | $11.19B |
| 22 | 179 of 463 | VRTX Vertex Pharmaceuticals | 34.7 | $136.56B |
| 23 | 186 of 463 | BIIB Biogen | 109.2 | $37.46B |
| 24 | 190 of 463 | AMGN Amgen | 27.0 | $251.89B |
| 25 | 192 of 463 | TECH Bio-Techne | 66.8 | $11.44B |
| 26 | 198 of 463 | COR Cencora | 20.0 | $68.51B |
| 27 | 207 of 463 | BAX Baxter International | — | $13.35B |
| 28 | 219 of 463 | LH Labcorp | 30.4 | $30.08B |
| 29 | 221 of 463 | ZBH Zimmer Biomet | 26.1 | $19.53B |
| 30 | 248 of 463 | BDX Becton, Dickinson | 43.1 | $59.39B |
| 31 | 249 of 463 | PFE Pfizer | 41.3 | $164.67B |
| 32 | 257 of 463 | A Agilent Technologies | 34.3 | $49.05B |
| 33 | 258 of 463 | VEEV Veeva Systems | 49.4 | $48.82B |
| 34 | 265 of 463 | EW Edwards Lifesciences | 60.5 | $61.61B |
| 35 | 268 of 463 | TMO Thermo Fisher Scientific | 36.9 | $259.44B |
| 36 | 269 of 463 | ALGN Align Technology | 24.5 | $11.86B |
| 37 | 270 of 463 | CRL Charles River Laboratories International | 348.4 | $16.19B |
| 38 | 276 of 463 | RMD ResMed | 21.8 | $33.69B |
| 39 | 293 of 463 | MDT Medtronic | 25.3 | $131.57B |
| 40 | 295 of 463 | WAT Waters | 197.5 | $90.45B |
| 41 | 296 of 463 | IDXX IDEXX Laboratories | 47.5 | $55.48B |
| 42 | 308 of 463 | DHR Danaher | 38.1 | $163.94B |
| 43 | 316 of 463 | COO Cooper Companies | 21.5 | $11.91B |
| 44 | 349 of 463 | GEHC GE HealthCare Technologies | 17.5 | $37.54B |
| 45 | 360 of 463 | IQV IQVIA | 32.3 | $43.69B |
| 46 | 361 of 463 | MTD Mettler-Toledo International | 37.7 | $34.59B |
| 47 | 391 of 463 | ISRG Intuitive Surgical | 53.7 | $153.77B |
| 48 | 392 of 463 | INCY Incyte | 64.3 | $24.66B |
| 49 | 405 of 463 | SYK Stryker | 33.0 | $117.88B |
| 50 | 406 of 463 | PODD Insulet | 24.9 | $10.58B |
| 51 | 409 of 463 | SOLV Solventum | 101.2 | $15.14B |
| 52 | 413 of 463 | STE STERIS | 31.4 | $25.67B |
| 53 | 419 of 463 | ZTS Zoetis | 14.1 | $34.06B |
| 54 | 422 of 463 | GILD Gilead Sciences | — | $208.48B |
| 55 | 442 of 463 | BSX Boston Scientific | 18.8 | $64.27B |
| 56 | 449 of 463 | ABT Abbott Laboratories | 40.3 | $187.95B |
| — | not scored today | DVA DaVita | 12.9 | $10.98B |
| — | not scored today | HCA HCA Healthcare | 16.6 | $104.25B |
| — | not scored today | MRNA Moderna | — | $90.38B |
"—" under P/E: no positive P/E (negative trailing earnings or missing at the source). 3 stocks do not get a multi-factor score today because a factor is missing; they go last, alphabetically. The full S&P 500 ranking →
Healthcare P/E against the index
| Median P/E | Companies with a positive P/E | |
|---|---|---|
| Healthcare | 32.8 | 55 of 59 |
| S&P 500 | 23.5 | 475 of 500 |
The median is the company in the middle: a few firms with near-zero earnings and huge P/Es do not move it, which is what happens to the average. Loss-making companies have no P/E and are left out.
Guide: P/E ratio explained · all guides
The 10 largest in the sector by market cap
| # | Company | Market cap | Weight in sector | Rank today |
|---|---|---|---|---|
| 1 | LLY Eli Lilly | $1.29T | 18.2% | 49 |
| 2 | JNJ Johnson & Johnson | $687.89B | 9.7% | 140 |
| 3 | ABBV AbbVie | $521.50B | 7.4% | 67 |
| 4 | UNH UnitedHealth | $365.09B | 5.2% | 153 |
| 5 | MRK Merck | $364.26B | 5.2% | 172 |
| 6 | TMO Thermo Fisher Scientific | $259.44B | 3.7% | 268 |
| 7 | AMGN Amgen | $251.89B | 3.6% | 190 |
| 8 | GILD Gilead Sciences | $208.48B | 3.0% | 422 |
| 9 | ABT Abbott Laboratories | $187.95B | 2.7% | 449 |
| 10 | PFE Pfizer | $164.67B | 2.3% | 249 |
Total market value (price times shares outstanding), without the float adjustment S&P applies: the weight is indicative. Companies with two share classes count once.
Insider buying and selling in the last 30 days
From Oct 14, 2026 to Nov 13, 2026, 1 open-market purchase ($2.0M) and 86 sales ($527.7M), filed on SEC Form 4 by directors, officers and 10% owners of 33 companies in the sector. Counted by trade date; grants, option exercises and transfers between the same insider's accounts are left out.
| Company | Buys | Amount | Sales | Amount |
|---|---|---|---|---|
| SYK Stryker | 0 | — | 1 | $178.9M |
| DVA DaVita | 0 | — | 1 | $69.0M |
| REGN Regeneron Pharmaceuticals | 0 | — | 9 | $49.6M |
| INCY Incyte | 0 | — | 3 | $28.8M |
| IDXX IDEXX Laboratories | 0 | — | 4 | $27.4M |
| GILD Gilead Sciences | 0 | — | 7 | $26.5M |
| ISRG Intuitive Surgical | 0 | — | 13 | $19.7M |
| HCA HCA Healthcare | 0 | — | 4 | $18.3M |
| MRNA Moderna | 0 | — | 2 | $17.0M |
| DHR Danaher | 0 | — | 4 | $13.4M |
| ABBV AbbVie | 0 | — | 1 | $11.9M |
| CRL Charles River Laboratories International | 0 | — | 2 | $9.2M |
| DGX Quest Diagnostics | 0 | — | 3 | $8.8M |
| EW Edwards Lifesciences | 0 | — | 3 | $7.5M |
| LLY Eli Lilly | 0 | — | 1 | $7.0M |
| VRTX Vertex Pharmaceuticals | 0 | — | 1 | $6.3M |
| MDT Medtronic | 0 | — | 2 | $5.8M |
| ELV Elevance Health | 0 | — | 2 | $5.2M |
| STE STERIS | 0 | — | 2 | $2.7M |
| HUM Humana | 0 | — | 2 | $2.6M |
| MCK McKesson | 0 | — | 3 | $2.1M |
| CVS CVS Health | 1 | $2.0M | 0 | — |
| TMO Thermo Fisher Scientific | 0 | — | 1 | $2.0M |
| VEEV Veeva Systems | 0 | — | 1 | $1.6M |
| RMD ResMed | 0 | — | 2 | $1.3M |
| LH Labcorp | 0 | — | 3 | $1.2M |
| IQV IQVIA | 0 | — | 1 | $1.2M |
| MTD Mettler-Toledo International | 0 | — | 1 | $754k |
| BDX Becton, Dickinson | 0 | — | 2 | $644k |
| ABT Abbott Laboratories | 0 | — | 1 | $406k |
| DXCM DexCom | 0 | — | 2 | $347k |
| COR Cencora | 0 | — | 1 | $326k |
| BMY Bristol-Myers Squibb | 0 | — | 1 | $241k |
Upcoming earnings dates
Dates announced by the companies themselves, from Nasdaq's public calendar (between Nov 13, 2026 and Dec 17, 2026). They are announcements, not measured dates: each company's SEC history is on its earnings page.
| Date | Company | When |
|---|---|---|
| Nov 19, 2026 | VEEV Veeva Systems | no time announced |
| Nov 23, 2026 | A Agilent Technologies | after the close |
| Nov 24, 2026 | MDT Medtronic | before the open |
| Dec 3, 2026 | COO Cooper Companies | after the close |
Who reports this week across the S&P 500 →
The other S&P 500 sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Industrials
- Real Estate
- Technology
- Utilities
Dividend yields in Healthcare and across the S&P 500 →
Sources: sector classification, market cap and P/E from the market-data provider (Yahoo Finance), as of the latest close downloaded; Quant500 multi-factor ranking of Nov 13, 2026; SEC Form 4 (EDGAR); Nasdaq public calendar. P/E is trailing twelve months and the median is taken per company, not per share class. Not investment advice.